journal article·2026-07Open access

Innovative strategies for diabetic peripheral neuropathy: From clinical management to emerging bioengineering solutions

Zhi He, Jie Diao, Frederick G. Hamel, Bin Duan

Abstract

Diabetic peripheral neuropathy (DPN) is a common, incurable complication of diabetes that causes sensory loss, pain, and motor problems. Conventional treatments like blood glucose management, pain relief, and neuroprotective drugs have limited success and do not prevent disease progression. Advances in neurobiology, regenerative medicine, and bioengineering have led to novel therapies that target underlying mechanisms and promote regeneration. Monitoring and evaluating the onset and progression of DPN are essential for effective clinical management. Given rapid advances in understanding DPN and developing new treatments, a comprehensive review that covers clinical progress, molecular pathology techniques, and emerging bioengineering strategies is both timely and essential. This review addresses: (1) DPN pathophysiology; (2) drug therapies from clinical trials since 2020; (3) animal models used in DPN research; (4) progress and challenges in biomaterial-based drug delivery systems; (5) developments and limitations of microfluidic platforms for DPN modeling; and (6) bioengineered devices used for DPN diagnosis and monitoring. Integrating clinical insights, molecular techniques, and bioengineering innovations seeks to create a forward-looking framework for next-generation DPN treatment and management.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Pain Mechanisms and Treatments · Diabetic Foot Ulcer Assessment and Management · Nerve injury and regeneration

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. The conundrum of diabetic neuropathies-Past, present, and future10.1016/j.jdiacomp.2022.108334 ↗
2. Mechanism of diabetic neuropathy: where are we now and where to go?10.1111/j.2040-1124.2010.00070.x ↗
3. Diabetic neuropathy: cutting-edge research and future directions10.1038/s41392-025-02175-1 ↗
4. Pharmacological and nonpharmacological treatments for painful diabetic peripheral neuropathy10.4093/dmj.2023.0018 ↗
5. Nanotechnology for pain management: current and future therapeutic interventions10.1016/j.nantod.2021.101223 ↗
6. Advances in nerve injury models on a chip
7. Recent advances in diagnostic strategies for diabetic peripheral neuropathy10.3803/EnM.2016.31.2.230 ↗
8. A scoping review of wearable technologies for use in individuals with intellectual disabilities and diabetic peripheral neuropathy10.1177/19322968241231279 ↗
9. Diagnosis and classification of diabetes mellitus10.2337/dc12-s064 ↗
10. Pathophysiology of diabetic dyslipidemia10.5551/jat.RV17023 ↗
11. Diabetic neuropathy: a position statement by the American diabetes association10.2337/dc16-2042 ↗
12. Diabetic peripheral neuropathy: pathogenetic mechanisms and treatment
13. New perspectives in diabetic neuropathy10.1016/j.neuron.2023.05.003 ↗
14. Is diabetes the risk factor for poor neurological recovery after cervical spine surgery? A review of the literature10.1186/s40001-022-00879-6 ↗
15. Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments10.1016/S1474-4422(22)00188-0 ↗
16. How inflammation dictates diabetic peripheral neuropathy: an enlightening review10.1111/cns.14477 ↗
17. Hyperglycemia magnifies Schwann cell dysfunction and cell death triggered by PA-induced lipotoxicity10.1016/j.brainres.2010.11.013 ↗
18. Mediators of diabetic neuropathy: is hyperglycemia the only culprit?10.1097/MED.0000000000000320 ↗
19. Effect of combined dyslipidemia and hyperglycemia on diabetic peripheral neuropathy in alloxan-induced diabetic WBN/Kob rats10.1293/tox.2017-0063 ↗
20. Diabetic neuropathy: clinical manifestations and current treatments10.1016/S1474-4422(12)70065-0 ↗
21. Diabetic neuropathy10.1038/s41572-019-0092-1 ↗
22. Diabetes microvascular complications-A clinical update10.1016/j.dsx.2016.12.022 ↗
23. Polyol pathway and redox balance in diabetes10.1016/j.phrs.2022.106326 ↗
24. Oxidative stress in diabetic peripheral neuropathy: pathway and mechanism-based treatment10.1007/s12035-023-03342-7 ↗
25. An insight into potential pharmacotherapeutic agents for painful diabetic neuropathy10.1155/2022/9989272 ↗
26. Pathogenesis and molecular treatment strategies of diabetic neuropathy collateral glucose-utilizing pathways in diabetic polyneuropathy10.3390/ijms22010094 ↗
27. The hexosamine biosynthesis pathway: regulation and function10.3390/genes14040933 ↗
28. Diabetic neuropathy: mechanisms to management10.1016/j.pharmthera.2008.05.005 ↗
29. Pyruvate dehydrogenase kinases: therapeutic targets for diabetes and cancers10.4093/dmj.2015.39.3.188 ↗
30. Emerging roles of lactate in acute and chronic inflammation10.1186/s12964-024-01624-8 ↗
31. Metabolic connection of inflammatory pain: pivotal role of a pyruvate dehydrogenase kinase-pyruvate dehydrogenase-lactic acid axis10.1523/JNEUROSCI.1910-15.2015 ↗
32. Pyruvate administration restores impaired nociception by enhancing neurite outgrowth in streptozotocin-induced diabetic mice10.3390/ijms26104666 ↗
33. The role of protein kinase C activation and the vascular complications of diabetes10.1016/j.phrs.2007.04.016 ↗
34. The role of protein kinases in diabetic neuropathic pain: an update review10.1007/s40200-023-01217-1 ↗
35. The discovery of LOX-1, its ligands and clinical significance10.1007/s10557-011-6324-6 ↗
36. Evolving concepts on the role of dyslipidemia, bioenergetics, and inflammation in the pathogenesis and treatment of diabetic peripheral neuropathy10.1111/jns.12387 ↗
37. Lipids: a suitable therapeutic target in diabetic neuropathy?10.1155/2017/6943851 ↗
38. Dyslipidemia impairs mitochondrial trafficking and function in sensory neurons10.1096/fj.201700206R ↗
39. PKCdelta knockdown inhibits free fatty acid induction of endothelial cell apoptosis10.1002/cbf.2908 ↗
40. Association of serum cholesterol levels with peripheral nerve damage in patients with type 2 diabetes10.1001/jamanetworkopen.2019.4798 ↗
41. Oxysterol levels and metabolism in the course of neuroinflammation: insights from in vitro and in vivo models10.1186/s12974-018-1114-8 ↗
42. Modulation of sensory nerve function by insulin: possible relevance to pain, inflammation and axon growth10.3390/ijms21072507 ↗
43. Disrupting insulin signaling in schwann cells impairs myelination and induces a sensory neuropathy10.1002/glia.23755 ↗
44. The impact of low-dose insulin on peripheral nerve insulin receptor signaling in streptozotocin-induced diabetic rats10.1371/journal.pone.0074247 ↗
45. A role for insulin in diabetic neuropathy10.3389/fnins.2016.00581 ↗
46. Dysregulation of PI3K-Akt-mTOR pathway in brain of streptozotocin-induced type 2 diabetes mellitus in Wistar rats10.1186/s12944-018-0809-2 ↗
47. IFN-gamma/mTORC1 decreased Rab11 in Schwann cells of diabetic peripheral neuropathy, inhibiting cell proliferation via GLUT1 downregulation10.1002/jcp.29510 ↗
48. The Akt/mTOR cascade mediates high glucose-induced reductions in BDNF via DNMT1 in Schwann cells in diabetic peripheral neuropathy10.1016/j.yexcr.2019.111502 ↗
49. Diabetes mellitus and Alzheimer's disease: GSK-3beta as a potential link10.1016/j.bbr.2017.11.015 ↗
50. NGF attenuates high glucose-induced ER stress, preventing schwann cell apoptosis by activating the PI3K/Akt/GSK3beta and ERK1/2 pathways10.1007/s11064-017-2333-6 ↗
51. The mechanisms of glycemic variability accelerate diabetic central neuropathy and diabetic peripheral neuropathy in diabetic rats10.1016/j.bbrc.2018.12.179 ↗
52. Targeting PI3K/AKT and MEK/ERK pathways for synergic effects on improving features of peripheral diabetic neuropathy10.1111/jdi.14289 ↗
53. Piperlongumine attenuates oxidative stress, inflammatory, and apoptosis through modulating the GLUT-2/4 and AKT signaling pathway in streptozotocin-induced diabetic rats10.1002/jbt.22763 ↗
54. Crosstalk between MiRNAs/lncRNAs and PI3K/AKT signaling pathway in diabetes mellitus: mechanistic and therapeutic perspectives10.1016/j.ncrna.2024.01.005 ↗
55. Painful diabetic neuropathy: the need for new approaches10.1177/19322968221132252 ↗
56. Diabetic neuropathic pain: directions for exploring treatments10.3390/biomedicines12030589 ↗
57. Update on treating painful diabetic peripheral neuropathy: a review of current US guidelines with a focus on the Most recently approved management options10.2147/JPR.S442595 ↗
58. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision10.1111/j.1468-1331.2010.02999.x ↗
59. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain10.1007/s10067-014-2517-2 ↗
60. Diagnosis and treatment of painful diabetic peripheral neuropathy10.2337/db2022-01 ↗
61. Diabetic peripheral neuropathy essentials: a narrative review10.21037/apm-22-693 ↗
62. Combined minimally invasive vagal cranial nerve and trigeminocervical complex peripheral nerve stimulation produces prolonged improvement of severe painful peripheral neuropathy and hyperglycemia in type 2 diabetes10.3389/fnins.2025.1644961 ↗
63. Safety and efficacy of magnetic peripheral nerve stimulation for treating painful diabetic neuropathy10.1016/j.neurom.2025.03.074 ↗
64. Using plantar electrical stimulation to improve postural balance and plantar sensation among patients with diabetic peripheral neuropathy: a randomized double blinded study10.1177/1932296817695338 ↗
65. Safety and efficacy of axon therapy (SEAT study), utilizing magnetic peripheral nerve stimulation (mPNS) for treatment of neuropathic pain10.2147/JPR.S481944 ↗
66. Spinal cord stimulation for painful diabetic neuropathy10.1177/19322968221133795 ↗
67. Novel TMS for stroke and depression (NoTSAD): accelerated repetitive transcranial magnetic stimulation as a safe and effective treatment for post-stroke depression10.3389/fneur.2020.00788 ↗
68. Emerging therapeutic modalities and pharmacotherapies in neuropathic pain management: a systematic review and meta-analysis of parallel randomized controlled trials10.1155/prm/6782574 ↗
69. Explore the effect of low-intensity focused ultrasound on pain relief in patients with diabetic peripheral neuropathy: a pilot randomized trial10.1002/jum.16716 ↗
70. Diabetic neuropathy research: from mouse models to targets for treatment10.4103/1673-5374.259603 ↗
71. Bodman, M.A., M.A. Dreyer, and M.A. Varacallo, Diabetic Peripheral Neuropathy. BTI - StatPearls.
72. Animal models of diabetic neuropathy: progress since 1960s10.1155/2013/149452 ↗
73. Navigating preclinical models and medications for peripheral neuropathy: a review10.3390/ph17081010 ↗
74. Animal models and biomarkers of neuropathy in diabetic rodents10.4103/0253-7613.66833 ↗
75. Rodent models of painful diabetic neuropathy: what can we learn from them?10.4172/2155-6156.S5-008 ↗
76. Soluble epoxide hydrolase inhibition alleviates neuropathy in Akita (Ins2 Akita) mice10.1016/j.bbr.2017.02.048 ↗
77. Changes in immunoreactivity of sensory substances within the enteric nervous system of the porcine stomach during experimentally induced diabetes10.1155/2018/4735659 ↗
78. Morphological changes and immunohistochemical expression of RAGE and its ligands in the sciatic nerve of hyperglycemic pig (Sus scrofa)
79. Early detection of cardiovascular autonomic neuropathy in diabetic pigs using blood pressure and heart rate variability10.1016/S0008-6363(99)00406-X ↗
80. Animal models of diabetic microvascular complications: relevance to clinical features10.1016/j.biopha.2021.112305 ↗
81. Chronically streptozocin-diabetic monkey does not closely mimic human diabetic neuropathy10.1016/S0014-4886(89)80006-8 ↗
82. Experimental diabetic animal models to study diabetes and diabetic complications10.1016/j.mex.2023.102474 ↗
83. Current advancement in the preclinical models used for the assessment of diabetic neuropathy10.1007/s00210-023-02802-0 ↗
84. Neuritic dystrophy and neuronopathy in Akita (Ins2(Akita)) diabetic mouse sympathetic ganglia10.1016/j.expneurol.2008.11.019 ↗
85. Downregulation of neuronal nitric oxide synthase (nNOS) within the paraventricular nucleus in Ins2(Akita)-type-1 diabetic mice contributes to sympatho-excitation10.1016/j.niox.2024.11.001 ↗
86. Impaired nociception in the diabetic Ins2(+/Akita) mouse10.2337/db17-1306 ↗
87. Transcriptional profiling of diabetic neuropathy in the BKS db/db mouse: a model of type 2 diabetes10.2337/db10-1541 ↗
88. Transgenic zebrafish as a model for investigating diabetic peripheral neuropathy: investigation of the role of insulin signaling10.3389/fncel.2024.1441827 ↗
89. Genetically engineered pig models for diabetes research10.1007/s11248-013-9755-y ↗
90. Porcine models for studying complications and organ crosstalk in diabetes mellitus10.1007/s00441-019-03158-9 ↗
91. Permanent neonatal diabetes in INS(C94Y) transgenic pigs10.2337/db12-1065 ↗
92. Genetically modified large animal models for investigating neurodegenerative diseases10.1186/s13578-021-00729-8 ↗
93. Animal models for type 1 and type 2 diabetes: advantages and limitations10.3389/fendo.2024.1359685 ↗
94. From mice to monkeys? Beyond Orthodox approaches to the ethics of animal model choice
95. Biopharma dives into tumor-seeking radioactive drugs10.1038/s41587-025-02681-1 ↗
96. Three-dimensional Co-culture model for live imaging of pancreatic islets, immune cells, and neurons in agarose gel10.21769/BioProtoc.4852 ↗
97. Insulin enhances neurite extension and myelination of diabetic neuropathy neurons10.3344/kjp.2022.35.2.160 ↗
98. Development of a 3-dimensional organotypic model with characteristics of peripheral sensory nerves
99. Simultaneous induction of vasculature and neuronal network formation on a chip reveals a dynamic interrelationship between cell types10.1186/s12964-023-01159-4 ↗
100. Distal degenerative sensory neuropathy in a long-term type 2 diabetes rat model10.2337/db07-1737 ↗